Article
The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer
26 Sept 2023
Abstract excerpt
Aberrant androgen receptor (AR) signaling drives prostate cancer (PC), and it is a key therapeutic target. Although initially effective, the generation of alternatively spliced AR variants (AR-Vs) compromises efficacy of treatments. In contrast to full-length AR (AR-FL), AR-Vs constitutively activate androgenic signaling and are refractory to the current repertoire of AR-targeting therapies, which together drive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
